CSF1R and Alzheimer disease: A chronic administration of a CSF1R inhibitor (PLX5622) in 5xFAD AD mice prevented Aβ plaque formation in areas devoid of microglia and altered the hippocampal gene expression, yet failed to improve neurological deficits [92].